Leerink Partners analyst Mani Foroohar maintained a Buy rating on RegenXBio (RGNX – Research Report) on February 20 and set a price target of ...

In a report released on February 19, Mike Kratky from Leerink Partners reiterated a Buy rating on Penumbra (PEN – Research Report), with a ...

Leerink Partnrs lowered their FY2028 earnings per share estimates for Axsome Therapeutics in a research note issued on ...

The U.S. Food and Drug Administration said on Friday there was no longer a shortage of Novo Nordisk's popular weight-loss and ...

Stock analysts at Leerink Partnrs upped their Q1 2025 earnings per share (EPS) estimates for Neurocrine Biosciences in a report issued on Monday, February 17th. Leerink Partnrs analyst M. Goodman now ...

Fintel reports that on February 18, 2025, Leerink Partners initiated coverage of aTyr Pharma (NasdaqCM:ATYR) with a ...

An investment banker who left Goldman Sachs & Co. for Leerink Partners LLC advanced part of her lawsuit saying she was denied promised bonuses and deferred grant awards worth millions of dollars. The ...

Fintel reports that on February 6, 2025, Leerink Partners downgraded their outlook for Hologic (NasdaqGS:HOLX) from Outperform to Market Perform. Analyst Price Forecast Suggests 20.21% Upside As ...

Fintel reports that on February 5, 2025, Leerink Partners upgraded their outlook for Regeneron Pharmaceuticals (WBAG:REGN) from Market Perform to Outperform. There are 2,472 funds or institutions ...